Aligos Enterprise Value Over E B I T D A from 2010 to 2024
| ALGS Stock | USD 0.83 0.01 1.22% |
Enterprise Value Over EBITDA | First Reported 2010-12-31 | Previous Quarter 0.97165615 | Current Value 1.02 | Quarterly Volatility 12.05189593 |
Check Aligos TherapeuticsInc financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aligos main balance sheet or income statement drivers, such as Tax Provision of 834.8 K, Net Interest Income of 1.3 M or Interest Income of 1 M, as well as many exotic indicators such as Price To Sales Ratio of 2.61, Dividend Yield of 0.0 or PTB Ratio of 0.49. Aligos financial statements analysis is a perfect complement when working with Aligos TherapeuticsInc Valuation or Volatility modules.
Aligos | Enterprise Value Over E B I T D A |
Latest Aligos TherapeuticsInc's Enterprise Value Over E B I T D A Growth Pattern
Below is the plot of the Enterprise Value Over E B I T D A of Aligos TherapeuticsInc over the last few years. It is Aligos TherapeuticsInc's Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Aligos TherapeuticsInc's overall financial position and show how it may be relating to other accounts over time.
| Enterprise Value Over E B I T D A | 10 Years Trend |
|
Enterprise Value Over E B I T D A |
| Timeline |
Aligos Enterprise Value Over E B I T D A Regression Statistics
| Arithmetic Mean | (15.16) | |
| Geometric Mean | 7.25 | |
| Coefficient Of Variation | (79.52) | |
| Mean Deviation | 11.33 | |
| Median | (24.59) | |
| Standard Deviation | 12.05 | |
| Sample Variance | 145.25 | |
| Range | 25.6133 | |
| R-Value | 0.87 | |
| Mean Square Error | 38.02 | |
| R-Squared | 0.76 | |
| Significance | 0.000025 | |
| Slope | 2.34 | |
| Total Sum of Squares | 2,033 |
Aligos Enterprise Value Over E B I T D A History
About Aligos TherapeuticsInc Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Aligos TherapeuticsInc income statement, its balance sheet, and the statement of cash flows. Aligos TherapeuticsInc investors use historical funamental indicators, such as Aligos TherapeuticsInc's Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Although Aligos TherapeuticsInc investors may use each financial statement separately, they are all related. The changes in Aligos TherapeuticsInc's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Aligos TherapeuticsInc's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Aligos TherapeuticsInc Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Aligos TherapeuticsInc. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Enterprise Value Over EBITDA | 0.97 | 1.02 |
Pair Trading with Aligos TherapeuticsInc
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aligos TherapeuticsInc position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aligos TherapeuticsInc will appreciate offsetting losses from the drop in the long position's value.Moving together with Aligos Stock
| 0.89 | VKTX | Viking Therapeutics Potential Growth | PairCorr |
| 0.9 | ELEV | Elevation Oncology Earnings Call This Week | PairCorr |
Moving against Aligos Stock
| 0.43 | GILD | Gilead Sciences Earnings Call Today | PairCorr |
The ability to find closely correlated positions to Aligos TherapeuticsInc could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aligos TherapeuticsInc when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aligos TherapeuticsInc - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aligos TherapeuticsInc to buy it.
The correlation of Aligos TherapeuticsInc is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aligos TherapeuticsInc moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aligos TherapeuticsInc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aligos TherapeuticsInc can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Aligos TherapeuticsInc Correlation against competitors. For more information on how to buy Aligos Stock please use our How to Invest in Aligos TherapeuticsInc guide.Note that the Aligos TherapeuticsInc information on this page should be used as a complementary analysis to other Aligos TherapeuticsInc's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Complementary Tools for Aligos Stock analysis
When running Aligos TherapeuticsInc's price analysis, check to measure Aligos TherapeuticsInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aligos TherapeuticsInc is operating at the current time. Most of Aligos TherapeuticsInc's value examination focuses on studying past and present price action to predict the probability of Aligos TherapeuticsInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aligos TherapeuticsInc's price. Additionally, you may evaluate how the addition of Aligos TherapeuticsInc to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |
Is Aligos TherapeuticsInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aligos TherapeuticsInc. If investors know Aligos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aligos TherapeuticsInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.36) | Revenue Per Share 0.242 | Quarterly Revenue Growth (0.24) | Return On Assets (0.37) | Return On Equity (0.89) |
The market value of Aligos TherapeuticsInc is measured differently than its book value, which is the value of Aligos that is recorded on the company's balance sheet. Investors also form their own opinion of Aligos TherapeuticsInc's value that differs from its market value or its book value, called intrinsic value, which is Aligos TherapeuticsInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aligos TherapeuticsInc's market value can be influenced by many factors that don't directly affect Aligos TherapeuticsInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aligos TherapeuticsInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Aligos TherapeuticsInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aligos TherapeuticsInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.